Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04645693
Other study ID # 843328
Secondary ID R01DE029648-01
Status Recruiting
Phase
First received
Last updated
Start date February 24, 2021
Est. completion date March 2025

Study information

Verified date April 2024
Source University of Pennsylvania
Contact Temitope Omolehinwa
Phone 2159085667
Email PDM-OHART@dental.upenn.edu
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a prospective cohort study designed to investigate the range of metabolic abnormalities observed in patients living with HIV on antiretroviral therapy. This study will also explore the concurrent role of poor oral health in supporting and driving chronic immune activation and inflammation in HIV infection.


Description:

This is a prospective cohort study designed to investigate the range of metabolic abnormalities observed in patients living with HIV (PLWH) on antiretroviral therapy (ART). This study will also explore the concurrent role of poor oral health in supporting and driving chronic immune activation and inflammation in HIV infection. Following enrollment in study, patients will be followed up every 6 months for approximately 2.5 years (30 months). During this period, comprehensive medical records will be obtained, and study data will be updated every 6 months; questionnaires will be handed to patients periodically to assess quality of life and effects of xerostomia on QoL; social history will be assessed using TAPS; oral health will be evaluated every 6 months and blood, saliva, and oral swabs collected every 6 months. DXA scan and panoramic radiographs will also be taken at baseline and 24 months. At the end of the study, caries rate, periodontal health, bone loss, QoL, salivary quantity and composition, presence or absence of white/red lesions, as well as inflammatory cytokines and immune activation markers will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 350
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Has been diagnosed with HIV (as documented by a prior laboratory report of positive HIV-1/2 antibody and/or detectable HIV RNA, available for review by the study team) - Has received antiretroviral therapy for at least 12 months - Able and willing to provide informed consent prior to initiation of study procedures - Willing and able to comply with all study procedures, and likely to be available for the duration of the study Exclusion Criteria: - Has been diagnosed with the following xerostomia-related autoimmune conditions: Sjorgen's and sarcoidosis - Has never received radiation therapy to the head or neck (including radioactive iodine therapy) - Was taking anti-osteoporotic agents (biphosphonates, denosumab) prior to HIV diagnosis. - Women who are pregnant at the time of enrollment.

Study Design


Locations

Country Name City State
United States University of Pennsylvania School of Dental Medicine Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pennsylvania National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dental Caries as assessed by DMFS Score Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. Baseline
Primary Dental Caries as assessed by DMFS Score Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. 6 months after baseline visit
Primary Dental Caries as assessed by DMFS Score Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. 12 months after baseline visit
Primary Dental Caries as assessed by DMFS Score Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. 18 months after baseline visit
Primary Dental Caries as assessed by DMFS Score Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. 24 months after baseline visit
Primary Dental Caries as assessed by DMFS Score Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. 30 months after baseline visit
Primary Periodontal disease Incidence of periodontal disease Baseline
Primary Periodontal disease Incidence of periodontal disease 12 months after baseline visit
Primary Periodontal disease Incidence of periodontal disease 24 months after baseline visit
Primary Periodontal disease Incidence of periodontal disease 30 months after baseline visit
Primary Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally Prescence or absence of warts, red or white lesions and candidia Baseline
Primary Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally Prescence or absence of warts, red or white lesions and candidia 6 months after baseline visit
Primary Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally Prescence or absence of warts, red or white lesions and candidia 12 months after baseline visit
Primary Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally Prescence or absence of warts, red or white lesions and candidia 18 months after baseline visit
Primary Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally Prescence or absence of warts, red or white lesions and candidia 24 months after baseline visit
Primary Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally Prescence or absence of warts, red or white lesions and candidia 30 months after baseline visit
Primary Osteopenia as assessed by DXA scan findings Incidence of osteopenia Baseline
Primary Osteopenia as assessed by DXA scan findings Incidence of osteopenia 24 months after baseline visit
Primary Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. Baseline
Primary Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. 12 months after baseline visit
Primary Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. 24 months after baseline visit
Primary Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. 30 months after baseline visit
Primary Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. Baseline
Primary Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. 12 months after baseline visit
Primary Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. 24 months after baseline visit
Primary Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. 30 months after baseline visit
Primary Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). Baseline
Primary Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). 12 months after baseline visit
Primary Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). 24 months after baseline visit
Primary Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). 30 months after baseline visit
Secondary Xerostomia as assessed by stimulated saliva secretion rate Prevalence of xerostomia Baseline
Secondary Xerostomia as assessed by stimulated saliva secretion rate Prevalence of xerostomia 6 months after baseline visit
Secondary Xerostomia as assessed by stimulated saliva secretion rate Prevalence of xerostomia 12 months after baseline visit
Secondary Xerostomia as assessed by stimulated saliva secretion rate Prevalence of xerostomia 18 months after baseline visit
Secondary Xerostomia as assessed by stimulated saliva secretion rate Prevalence of xerostomia 24 months after baseline visit
Secondary Xerostomia as assessed by stimulated saliva secretion rate Prevalence of xerostomia 30 months after baseline visit
Secondary Saliva proteins levels of amylase expression will be assessed Baseline
Secondary Saliva proteins levels of amylase expression will be assessed 6 months after baseline visit
Secondary Saliva proteins levels of amylase expression will be assessed 12 months after baseline visit
Secondary Saliva proteins levels of amylase expression will be assessed 18 months after baseline visit
Secondary Saliva proteins levels of amylase expression will be assessed 24 months after baseline visit
Secondary Saliva proteins levels of amylase expression will be assessed 30 months after baseline visit
Secondary Saliva proteins levels of IgA expression will be assessed baseline visit
Secondary Saliva proteins levels of IgA expression will be assessed 6 months after baseline visit
Secondary Saliva proteins levels of IgA expression will be assessed 12 months after baseline visit
Secondary Saliva proteins levels of IgA expression will be assessed 18 months after baseline visit
Secondary Saliva proteins levels of IgA expression will be assessed 24 months after baseline visit
Secondary Saliva proteins levels of IgA expression will be assessed 30 months after baseline visit
Secondary Correlative measures Salivary cytokines: levels of IL-6, IL-7, IL-10, TNF-a, neopterin, ß-2-microglobulin (ß2M) and monocyte chemotactic protein-1 will be assessed Baseline through 30 months
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2